Literature DB >> 33482806

C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.

Junhui Xu1, Xiaojuan Yu2, Suxia Wang3, Miao Yan1, Mangju Wang1, Jinping Ou1, Lihong Wang1, Huihui Liu1, Xinan Cen4.   

Abstract

BACKGROUND: Multiple myeloma causes different types of renal injury. C3 glomerulonephritis (C3GN) is characterised by an abnormal deposition of complement C3 in the glomeruli due to abnormal activation of the alternative pathway of the complement system. While the association between C3GN and multiple myeloma has been well established, mild renal injury by C3GN in multiple myeloma patients with high levels of light chain has not been reported. CASE
PRESENTATION: A 55-year-old Chinese man presented with proteinuria. Combined with immunofixation electrophoresis, bone marrow biopsy, and renal biopsy, he was diagnosed with IgA-type multiple myeloma accompanied by C3GN and light chain proximal tubulopathy without crystal deposits. Although he had a higher level of lambda serum-free light chain, the renal injury in this patient was mild. After treatment with four courses of BD, one course of PAD, and autologous stem cell transplantation, he achieved a very good partial hematologic response with stable renal function.
CONCLUSIONS: In multiple myeloma, the light chain reaches a certain level and persists, resulting in C3GN renal impairment. Early diagnosis and early intensive treatment are critical for the prognosis of such patients.

Entities:  

Keywords:  Autologous stem cell transplantation; C3 glomerulonephritis; Light Chain proximal tubulopathy without crystal deposits; Multiple myeloma

Mesh:

Year:  2021        PMID: 33482806      PMCID: PMC7824921          DOI: 10.1186/s12957-021-02135-3

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  8 in total

1.  Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?

Authors:  Frank Bridoux; Estelle Desport; Véronique Frémeaux-Bacchi; Christine Fen Chong; Jean-Marc Gombert; Corinne Lacombe; Nathalie Quellard; Guy Touchard
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

2.  Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.

Authors:  T S Jokiranta; A Solomon; M K Pangburn; P F Zipfel; S Meri
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

Review 3.  Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma.

Authors:  E Bourke; W G Campbell; M Piper; I J Check
Journal:  Nephron       Date:  1989       Impact factor: 2.847

Review 4.  Spectrum of manifestations of monoclonal gammopathy-associated renal lesions.

Authors:  Sanjeev Sethi; Fernando C Fervenza; S Vincent Rajkumar
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-03       Impact factor: 2.894

5.  The association of serum-free light-chain levels with markers of renal function.

Authors:  Bilge Karatoy Erdem; Fatih Davran; Vural Taner Yilmaz; Ramazan Çetinkaya; Halide Akbas
Journal:  Ren Fail       Date:  2015-06-09       Impact factor: 2.606

Review 6.  C3 glomerulonephritis in multiple myeloma: A case report and literature review.

Authors:  Guang Yin; Zhen Cheng; Cai-Hong Zeng; Zhi-Hong Liu
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

Review 7.  C3 glomerulonephritis and CFHR5 nephropathy.

Authors:  Daniel P Gale; Patrick H Maxwell
Journal:  Nephrol Dial Transplant       Date:  2012-11-02       Impact factor: 5.992

8.  Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.

Authors:  Punit Yadav; Paul Cockwell; Mark Cook; Jennifer Pinney; Hannah Giles; Yu Sandar Aung; David Cairns; Roger G Owen; Faith E Davies; Graham H Jackson; J Anthony Child; Gareth J Morgan; Mark T Drayson
Journal:  BMC Nephrol       Date:  2018-07-13       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.